Growth hormone signaling, IGF-1, recovery, body composition, sleep
CJC-1295 + Ipamorelin
A growth-hormone secretagogue pairing studied for stimulating endogenous GH/IGF-1 signaling, with research interest in body composition, recovery, sleep, and age-related changes in GH secretion.
Administration Reference
Subcutaneous
Source / Evidence Context
Commonly reported use — not established guidance
Formulation & Context
Common blends generally use short-acting CJC-1295 without DAC (no DAC) and Ipamorelin. CJC-1295 with DAC has substantially different pharmacokinetics and should not be treated as interchangeable.
Dose Information
100 mcg – 300 mcg per injection
Frequency
once daily to 2–3 times daily
Duration / Cycle
8–12 weeks
Off-Cycle
4 weeks
Timing
Before bed and fasted, 15 minutes prior to strength training.
Storage Guidance
Refrigerate after reconstitution and use within approximately 30 days, Freeze for lyophilized powder form
Supplies
Affiliate disclosure: We may earn a commission if you purchase through these links.
Listings are not a required kit or confirmation of suitability for a particular peptide, formulation, or route. Check the product specifications and intended use.
Syringes & transfer supplies
EasyTouch U-100 Insulin Syringes (31G 0.5cc 5/16″) – 100ct.U-100 Insulin Syringes (31G 0.5cc 5/16") – 100ctInsulin syringes – Polybag, 50 Unit Capacity, 5/16” Needle Length, Bold Markings for Accurate Dosing, Disposable, Box of 100View at AMAZON →
Protective supplies & disposal
MED PRIDE Sterile Alcohol Prep Pads1 BOX OF 200INDIVIDUALLY WRAPPED ISOPROPYL ALCOHOL WIPES, PACK OF 1 BOX OF 200, MEDIUM SIZE PREP PADSView at AMAZON →
Inspire Black Nitrile Gloves HEAVY DUTY 6 Mil100ctView at AMAZON →
Square Sharps Container, 2 QuartQTY 1View at AMAZON →
Commonly Reported Uses
Growth-hormone and IGF-1 research; recovery; lean-mass preservation; body-composition research; sleep-related research; tissue repair; age-related decline in GH secretion. Direct clinical evidence for the combination is limited.
Commonly Reported Indicators
Changes commonly discussed include sleep quality, recovery, body composition, fluid retention, and perceived exercise recovery. Serum IGF-1 is a measurable biological marker of GH-axis stimulation, although it does not establish clinical benefit.
Mechanism Overview
CJC-1295 analogues stimulate the GHRH receptor, increasing pituitary GH release. Ipamorelin acts through the ghrelin/GHS-R1a receptor and also stimulates GH secretion. The theoretical rationale for combining them is simultaneous stimulation through complementary signaling pathways. CJC-1295 with DAC has produced sustained GH and IGF-1 elevation in healthy adults, while ipamorelin has demonstrated dose-dependent GH release in human volunteers.
Safety
Safety Considerations
The combination itself lacks controlled human safety trials. CJC-1295 studies reported frequent injection-site reactions, headache, flushing, gastrointestinal effects, transient hypotension, dizziness, and increased heart rate. FDA has also raised immunogenicity and peptide-aggregation concerns. For ipamorelin, FDA notes that subcutaneous safety data are insufficient and that intravenous clinical research reported higher rates of hypokalemia and hyperglycemia.
Reported Adverse Effects
Injection-site irritation, erythema, pain or itching; headache; flushing; warmth; dizziness; transient hypotension; increased heart rate; nausea; abdominal discomfort; diarrhea; arthralgia; fluid retention; glucose intolerance or hyperglycemia. Long-term adverse-event rates are unknown.
Contraindications & Cautions
Particular caution is appropriate with active malignancy, impaired glucose regulation or diabetes, cardiovascular disease, significant fluid-retention disorders, pregnancy or breastfeeding, and conditions in which increased GH/IGF-1 signaling may be undesirable. Long-term safety in healthy adults has not been established.
Cancer Considerations
Editorial evidence assessment, not a validated risk score or clearance for use. Unknown risk does not mean low risk; these notes do not establish safety during active cancer or remission.
Cancer Concern Assessment
Elevated concern
Basis for Concern
Both compounds are intended to increase endogenous GH signaling, with CJC-1295 also producing sustained increases in IGF-1. The GH/IGF-1 axis is mitogenic and anti-apoptotic and can support proliferation of already transformed cells. Human evidence does not establish that GH stimulation itself causes cancer, but the mechanism creates a meaningful concern where malignancy already exists.
Active Cancer
Significant concern
There are no controlled studies establishing safety of CJC-1295, ipamorelin, or their combination in active malignancy. Because both increase GH-axis activity and GH/IGF-1 signaling can support tumor-cell proliferation and survival, active cancer warrants substantial caution.
Prior Cancer / Remission
Individualized caution
Direct recurrence-risk data for these peptides are unavailable. Research involving medically supervised GH replacement after prior malignancy is more reassuring than mechanistic concerns alone would suggest, but those findings cannot be assumed to apply to unapproved GH secretagogues. No validated remission interval exists for this combination.
Status
Regulatory Status
Neither CJC-1295 nor ipamorelin is FDA approved for treatment of growth-hormone deficiency, body-composition enhancement, recovery, anti-aging, or other therapeutic use. FDA advisory reviews recommended against adding CJC-1295-related and ipamorelin-related substances to the 503A Bulks List based on inadequate characterization, limited safety and effectiveness data, and identified safety concerns.
Development / Research Status
Human research compound
Market Classification
Research-use compound
Research & Evidence
Evidence Level
Human clinical research
Research Last Reviewed
2026-09-05
Research Overview
Both compounds have human pharmacology data individually, but evidence for the commonly marketed CJC-1295/ipamorelin combination is substantially weaker. CJC-1295 with DAC has demonstrated prolonged GH and IGF-1 elevation in healthy adults. Ipamorelin has demonstrated GH-releasing activity in healthy volunteers and has undergone clinical testing for postoperative ileus. Controlled trials of the combination for recovery, sleep, body composition, or anti-aging outcomes have not been established.
Human Research
Two randomized, placebo-controlled CJC-1295 studies examined healthy adults over 28–49 days. A single subcutaneous dose increased mean GH approximately 2- to 10-fold for six days or longer and IGF-1 approximately 1.5- to 3-fold for 9–11 days; estimated half-life was 5.8–8.1 days. Another study confirmed persistence of pulsatile GH secretion one week after CJC-1295 administration. For ipamorelin, a dose-escalation study in healthy men demonstrated dose-proportional pharmacokinetics, an approximately two-hour terminal half-life, and a distinct GH pulse peaking around 0.67 hours. A 114-patient postoperative-ileus trial found no statistically significant improvement in time to first tolerated meal with intravenous ipamorelin.
Animal Research
Preclinical research helped establish ipamorelin as a relatively selective GH secretagogue. Animal work demonstrated strong GH release with substantially less ACTH and cortisol stimulation than earlier GHRPs. CJC-1295-related research also demonstrated prolonged GH-axis stimulation before human development.
In Vitro Research
Mechanistic research supports two complementary receptor systems: GHRH-receptor signaling for CJC-1295 analogues and GHS-R1a/ghrelin-receptor signaling for ipamorelin. This provides biological plausibility for enhanced GH release when the pathways are stimulated together, but direct evidence establishing clinical synergy for the combination is lacking.